Meropenem Plasma Concentration Measurements at the Pediatric Medical Ward, Oslo University Hospital, Rikshospitalet
Information source: Oslo University Hospital
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Bacterial Infection
Phase: N/A
Status: Completed
Sponsored by: Oslo University Hospital Official(s) and/or principal investigator(s): Odd Brørs, Dr Med, Study Director, Affiliation: Oslo University Hospital Margrete L Burns, BMed, Study Chair, Affiliation: Oslo univeristy hospital Øystein Riise, PhD, Study Chair, Affiliation: Oslo University Hospital Tore Abrahamsen, Dr Med, Study Chair, Affiliation: Oslo univeristy hospital Gaut Gadeholt, Dr Med, Study Chair, Affiliation: Oslo University Hospital
Summary
The object of the study is to investigate whether all included patients receive treatment
that is effective against all bacteria that are defined as sensitive to meropenem with the
current treatment regimen. Will the investigators findings motivate routine monitoring of
plasma concentrations in children receiving meropenem? Up to 50 patients will be included in
the study, and all participants are children.
Clinical Details
Official title: Meropenem Plasma Concentration Measurements at the Pediatric Medical Ward, Oslo University Hospital, Rikshospitalet
Study design: Observational Model: Cohort, Time Perspective: Prospective
Primary outcome: We will determine how many of the patients in our material that have plasma concentrations of meropenem above 8 mg/l for at least 40% and 75% of the time.
Eligibility
Minimum age: 3 Months.
Maximum age: 18 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Children aged from 3 months to 18 years that receive treatment with meropenem.
Inclusion is independent of how long the patient has been receiving treatment.
Children receiving other treatment (except hemodialysis)/other medications can be
included.
Exclusion Criteria:
- Children less than three months of age. Patients receiving hemodialysis. Lack of
consent.
Locations and Contacts
Oslo univeristy hospital, Rikshospitalet, Oslo 0424, Norway
Additional Information
Related publications: Ikeda K, Ikawa K, Morikawa N, Miki M, Nishimura S, Kobayashi M. High-performance liquid chromatography with ultraviolet detection for real-time therapeutic drug monitoring of meropenem in plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Sep 1;856(1-2):371-5. Epub 2007 Jun 6.
Starting date: January 2011
Last updated: November 5, 2014
|